首页> 美国卫生研究院文献>Journal of Cancer >Safety Efficacy Pharmacokinetic and Pharmacodynamic evaluation of YF-H-2015005 for mobilizing Hematopoietic stem cells in Non-Hodgkins Lymphoma Patients

【2h】

Safety Efficacy Pharmacokinetic and Pharmacodynamic evaluation of YF-H-2015005 for mobilizing Hematopoietic stem cells in Non-Hodgkins Lymphoma Patients

机译：YF-H-2015005在非霍奇金淋巴瘤患者中造血干细胞的安全性疗效药代动力学和药效学评价

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

期刊名称 Journal of Cancer
作者
Weiping Liu; Yan Xie; Lingyan Ping; Min Jiang; Guanmin Zhang; Yimin Cui; Junyu Xu; Meng Wu; Xin Leng; Xiaopei Wang; Shufang Wang; Jun Zhu; Yuqin Song;
展开▼
作者单位

展开▼
年(卷),期 2020(11),19
年度 2020
页码 -1
总页数 6
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
Hematopoietic Stem Cell Mobilization; Drug Evaluation; Pharmacokinetics; Safety; Lymphoma; Non-Hodgkins;

相似文献

外文文献
中文文献
专利

1. Safety, Efficacy, Pharmacokinetic and Pharmacodynamic evaluation of YF-H-2015005 for mobilizing Hematopoietic stem cells in Non-Hodgkin's Lymphoma Patients [J] . Weiping Liu, Yan Xie, Lingyan Ping, Journal of Cancer . 2020,第19期

机译：YF-H-2015005在非霍奇金淋巴瘤患者中造血干细胞的安全性，疗效，药代动力学和药效学评价
2. YF-H-2015005, a CXCR4 Antagonist, for the Mobilization of Hematopoietic Stem Cells in Non-Hodgkin Lymphoma Patients: A Randomized, Controlled, Phase 3 Clinical Trial [J] . Weiping Liu, Ye Chai, Yicheng Zhang, Frontiers in Medicine . 2021,第a期

机译：CXCR4拮抗剂YF-H-2015005，用于在非霍奇金淋巴瘤患者中动员造血干细胞：随机，受控，第3期临床试验
3. The efficacy and safety of plerixafor in hematopoietic stem cell mobilization in patients with Non-Hodgkin lymphoma, multiple myeloma, and Hodgkin lymphoma who failed mobilization with granulocyte-colony-stimulating factor alone: A single-center experience [J] . Girish Badarkhe, Radheshyam Naik Indian Journal of Medical and Paediatric Oncology . 2020,第4期

机译：单独使用粒细胞 - 殖民地刺激因子的血管瘤淋巴瘤，多发性骨髓瘤和Hodgkin淋巴瘤患者血管生成干细胞动员的疗效和安全性：单独的经验
4. CLINICAL ADVANCEMENT OF A RNA-TRANSFECTED CD40-B CELL VACCINE FOR THE TREATMENT OF CANINE NON-HODGKIN'S LYMPHOMA [C] . Nicola Mason, Martha MalonevHuss, Josephine Gnanandarajah Conference of the American^College^of^Veterinary^Internal^Medicine . 2016

机译：RNA转染的CD40-B细胞疫苗治疗犬非霍奇金淋巴瘤的临床进展
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. YF-H-2015005 a CXCR4 Antagonist for the Mobilization of Hematopoietic Stem Cells in Non-Hodgkin Lymphoma Patients: A Randomized Controlled Phase 3 Clinical Trial [O] . Weiping Liu, Yufu Li, Quanshun Wang, 2021

机译：CXCR4拮抗剂YF-H-2015005用于在非霍奇金淋巴瘤患者中动员造血干细胞：随机受控第3期临床试验
7. Safety, Efficacy, Pharmacokinetic and Pharmacodynamic evaluation of YF-H-2015005 for mobilizing Hematopoietic stem cells in Non-Hodgkin's Lymphoma Patients [O] . Weiping Liu, Yan Xie, Lingyan Ping, 2020

机译：YF-H-2015005在非霍奇金淋巴瘤患者中造血干细胞的安全性，疗效，药代动力学和药效学评价

Safety Efficacy Pharmacokinetic and Pharmacodynamic evaluation of YF-H-2015005 for mobilizing Hematopoietic stem cells in Non-Hodgkins Lymphoma Patients

著录项

引文网络

相似文献

相关主题

期刊订阅